Drug Name: Vivjoa
Active Ingredient: oteseconazole
Indications: To reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are not of reproductive potential
Approval Date: 4/26/2022
Company: Mycovia Pharmaceuticals, Inc
Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215888s000lbl.pdf